

Expression levels of GATA1s isoform affect megakaryocyte differentiation and leukemic predisposition in mice

Daishi Ishihara, Atsushi Hasegawa, Ikuo Hirano, James Douglas Engel,
Masayuki Yamamoto and Ritsuko Shimizu

List of Supporting Information

Supplementary Fig. 1: Increase of megakaryocytes in Δ NTR-H and Δ NTR-M embryos

Supplementary Fig. 2: Histopathological analyses of liver sections of leukemic Δ NTR-M mice

Supplementary Fig. 3: Peripheral blood smear of a leukemic Δ NTR-M mouse

Supplementary Fig. 4: Autonomous proliferation of leukemic cells in recipient nude mice.

Supplementary Fig. 5: Integration sites of transgenes in the lines of mice expressing GATA1s.

Supplementary Table 1: List of mice used for Kaplan-Meier analysis.

Supplementary Table 2: Primer sequences used for mouse genotyping.


Supplementary Table 3: Primer sequences used for Identification of transgene insertion sites.

Supplementary Table 4: Primer sequences used for qPCR.

Supplementary information: Materials and Methods

Supplementary Fig. 1


Increase of megakaryocytes in Δ NTR-H and Δ NTR-M embryos



(A) Dot plot depicting the frequencies of CD41+CD61+ megakaryocytes in live cells from the fetal liver at E18.5. (B) Hematoxylin and eosin-stained sections of E12.5 Δ NTR-M and Δ NTR-H livers exhibit accumulation of large cells with a diameter exceeding 10 μ m (indicated by yellow arrowheads).

Supplementary Fig. 2


Histopathological analyses of liver sections of leukemic Δ NTR-M mice



Histopathological analyses on liver sections from two Δ NTR-M mice exhibiting splenomegaly and a control wild-type mouse. Hematoxylin-Eosin staining (left panels) and silver staining (right panels) are shown. d/o: days-old.

Supplementary Fig. 3


Peripheral blood smear of a leukemic Δ NTR-M mouse



A lower magnification image (upper panel) and an enlarged image (lower panel) of the inset are presented. In these images, multiple blast cells with or without bleb formation are observed, which are indicated by red and black arrows, respectively. Additionally, numerous smudge cells are present, suggesting a hematopoietic neoplastic disease.

Supplementary Fig. 4


Leukemic cells in Δ NTR-M mouse show autonomous proliferation in recipient nude mice.



(A-C) A leukemia-developing Δ NTR-M mouse of 76 days-old (d/o) used for the transplantation analysis. Results include the macroscopic appearance (A), May-Grünwald–Giemsa staining of a peripheral blood smear (B), and flow cytometry analysis of the spleen (C). (C) Cells are visualized on FSC versus SSC (left panel), and the abnormal cells gated in the red polygon are c-Kit-positive and CD41-dull (right panel). (D) Kaplan-Meier graph depicting the outcome of five nude mice transplanted with 1×10^6 splenic cells from the leukemia developing Δ NTR-M mouse shown in (A). (E) Representative images from macroscopic analysis of two nude mice at 45 days (Case 1; left) and 52 days (Case 2; right) after transplantation. The spleen, liver, and body weights of mice in Case 1 are 1.97 g, 3.33 g and 22.4 g, respectively, while those in Case 2 are 0.98 g, 1.79 g and 13.5 g, respectively. (F) Flow cytometry analysis of spleen mononuclear cells from the Case 1 nude mouse (left) and that from Case 2 nude mouse (right). Cells within the abnormal fractions, marked by small black polygons in both left panels, exhibited characteristics of c-Kit⁺CD41^{dull}, as seen in both right panels. (G) Blast cells in the peripheral blood smear sample (left panel) and cytopsin samples from bone marrow (middle panel) and spleen (right panel). These samples were collected from the Case 1 leukemic nude mouse. Note that these leukemic cells in the nude mice exhibit similar characteristics to those observed in the donor Δ NTR-M mouse.

Supplementary Fig. 5

Integration sites of transgenes in the Δ NT-H and Δ NT-M lines.



(A) Schematic representation of the G1HRD-G1 and G1HRD- Δ NT transgene constructs. Locations of primers used to identify the transgenes are indicated with blue arrows. (B, C) Schematic diagrams of the transgene-integrated sites on chromosome 3 in the Δ NT-H line of mice (B) and on chromosome 13 in the Δ NT-M line of mice (C). Notably, multiple copies (more than three [6]) of transgenes were integrated into the genomes of Δ NT-H and Δ NT-M transgenic mice. The orientations of the transgenes at both ends are depicted. Genomic position data is referenced from the GRCm38 mouse assembly. Locations of primers used to identify the transgenic and wild-type alleles are denoted with blue arrows. A reverse primer, specific for endogenous chromosome 13 allele, was designed within the sequence that was replaced by transgene in Δ NT-M line. We have determined that the transgene in the Δ NT-H mice is integrated

within the body of the *Ndst4* gene, which may represent a relatively open chromatin structure. In contrast, the transgene in Δ NT-M mice is in an intergenic region approximately 100 Mb away from the neighboring genes, suggesting a probable closed structure. We surmise that the difference in the *Gata1s* expression levels between the two transgenic mouse lines is attributable largely to the insertion site of the transgene.

Supplementary Table 1. List of mice used for experiment shown in Figure 1.

*: Mice that underwent necropsy

No.	ID	Age (day)	Genotype	Outcome
1	710	180	G1R	Surviving
2	957	180	G1R	Surviving
3	306	180	G1R	Surviving
4	308	180	G1R	Surviving
5	309	180	G1R	Surviving
6	310	180	G1R	Surviving
7	481	180	G1R	Surviving
8	487	180	G1R	Surviving
9	488	180	G1R	Surviving
10	491	180	G1R	Surviving
11	432	180	G1R	Surviving
12	183	180	G1R	Surviving
13	059	180	G1R	Surviving
14	738	180	G1R	Surviving
15	966	180	G1R	Surviving
16	298	77	Δ NTR-H	Unknown
17	441	180	Δ NTR-H	Surviving
18	496	180	Δ NTR-H	Surviving
19	501	180	Δ NTR-H	Surviving
20	433	180	Δ NTR-H	Surviving
21	434	180	Δ NTR-H	Surviving
22	435	180	Δ NTR-H	Surviving
23	436	180	Δ NTR-H	Surviving
24	350	180	Δ NTR-H	Surviving
25	222	180	Δ NTR-H	Surviving
26	187	180	Δ NTR-H	Surviving
27	724	180	Δ NTR-H	Surviving
28	727	180	Δ NTR-H	Surviving
29	188	180	Δ NTR-H	Surviving
30	191	180	Δ NTR-H	Surviving
31	195	180	Δ NTR-H	Surviving
32	448	180	Δ NTR-H	Surviving
33	351	180	Δ NTR-H	Surviving
34	619	180	Δ NTR-H	Surviving
35	029	180	Δ NTR-H	Surviving
36	030	180	Δ NTR-H	Surviving
37	484	180	Δ NTR-H	Surviving
38	779	180	Δ NTR-H	Surviving
39	223	180	Δ NTR-H	Surviving
40	083	180	Δ NTR-H	Surviving
41	670	180	Δ NTR-H	Surviving
42	672	180	Δ NTR-H	Surviving

Supplementary Table 1 (Continued)

No.	ID	Age (day)	Background	Outcome
43	673	180	Δ NTR-H	Surviving
44	674	180	Δ NTR-H	Surviving
45	031	180	Δ NTR-H	Surviving
46	061	180	Δ NTR-H	Surviving
47	005	180	Δ NTR-H	Surviving
48	808	180	Δ NTR-H	Surviving
49	470	180	Δ NTR-H	Surviving
50	482	180	Δ NTR-H	Surviving
51	337	180	Δ NTR-H	Surviving
52	653	180	Δ NTR-H	Surviving
53	174	180	Δ NTR-H	Surviving
54	176	180	Δ NTR-H	Surviving
55	165	180	Δ NTR-H	Surviving
56	166	180	Δ NTR-H	Surviving
57	167	180	Δ NTR-H	Surviving
58	198	180	Δ NTR-H	Surviving
59	104	180	Δ NTR-H	Surviving
60	101	180	Δ NTR-H	Surviving
61	102	180	Δ NTR-H	Surviving
62	194	180	Δ NTR-H	Surviving
63	957	180	Δ NTR-H	Surviving
64	491	180	Δ NTR-H	Surviving
65	329	180	Δ NTR-H	Surviving
66	782	180	Δ NTR-H	Surviving
67	964	180	Δ NTR-H	Surviving
68	684	180	Δ NTR-H	Surviving
69	017	33	Δ NTR-M	Unknown
70	199	33	Δ NTR-M	Unknown
71	044	35	Δ NTR-M	Unknown
72	414	35	Δ NTR-M	Unknown
73	* 592	38	Δ NTR-M	Leukemia
74	842	41	Δ NTR-M	Unknown
75	864	41	Δ NTR-M	Unknown
76	808	45	Δ NTR-M	Unknown
77	966	45	Δ NTR-M	Unknown
78	* 548	45	Δ NTR-M	Leukemia
79	* 723	45	Δ NTR-M	Leukemia
80	* 387	50	Δ NTR-M	Leukemia
81	728	52	Δ NTR-M	Unknown
82	757	52	Δ NTR-M	Unknown
83	* 724	53	Δ NTR-M	Leukemia
84	* 756	53	Δ NTR-M	Leukemia

Supplementary Table 1 (Continued)

No.	ID	Age (day)	Background	Outcome
85	693	60	Δ NTR-M	Unknown
86	721	60	Δ NTR-M	Unknown
87	130	67	Δ NTR-M	Unknown
88	209	67	Δ NTR-M	Unknown
89	384	88	Δ NTR-M	Unknown
90	* 071	93	Δ NTR-M	Leukemia
91	* 155	93	Δ NTR-M	Leukemia
92	* 162	120	Δ NTR-M	Leukemia
93	* 209	120	Δ NTR-M	Leukemia
94	* 337	143	Δ NTR-M	Leukemia
95	* 516	143	Δ NTR-M	Leukemia
96	* 494	146	Δ NTR-M	Leukemia
97	* 516	146	Δ NTR-M	Leukemia
98	* 663	149	Δ NTR-M	Leukemia
99	* 792	149	Δ NTR-M	Leukemia
100	* 094	150	Δ NTR-M	Leukemia
101	* 200	150	Δ NTR-M	Leukemia
102	* 396	162	Δ NTR-M	Leukemia
103	117	180	Δ NTR-M	Surviving
104	685	180	Δ NTR-M	Surviving
105	110	180	Δ NTR-M	Surviving
106	738	180	Δ NTR-M	Surviving
107	351	180	Δ NTR-M	Surviving
108	082	180	Δ NTR-MH	Surviving
109	471	180	Δ NTR-MH	Surviving
110	004	180	Δ NTR-MH	Surviving
111	009	180	Δ NTR-MH	Surviving
112	599	180	Δ NTR-MH	Surviving
113	427	180	Δ NTR-MH	Surviving
114	256	180	Δ NTR-MH	Surviving
115	470	180	Δ NTR-MH	Surviving
116	373	180	Δ NTR-MH	Surviving
117	148	180	Δ NTR-MH	Surviving
118	205	180	Δ NTR-MH	Surviving
119	088	180	Δ NTR-MH	Surviving
120	* 406	132	Δ NTR-MM	Leukemia
121	431	138	Δ NTR-MM	Unknown
122	657	180	Δ NTR-MM	Surviving
123	355	180	Δ NTR-MM	Surviving
124	071	180	Δ NTR-MM	Surviving
125	020	180	Δ NTR-MM	Surviving
126	151	180	Δ NTR-MM	Surviving

Supplementary Table 2. Primer sequences used for mouse genotyping.

		Primer sequence (5'-3')
<i>Gata1.05</i> allele	F	AAGTATCCATCATGGCTGATGC
	R	TAGCCAACGCTATGTCCTGATA
Y-chromosome	F	CCTATTGCATGGACTGCAGCTTATG
	R	GACTAGACATGTCTTAACATCTGTCC
G1HRD-G1 and G1HRD- Δ NT transgene	F	AGATGAATGGTCAGAACCGG
	R	AGGCATAAGATGGCTGACAG
Δ NT-M transgene	F	GGAGACAGGATCTTCTGTAGC
	R	GGGTGATTGGGTTACCTTACTC
Δ NT-H transgene	F	CCAGAGGATAGAGAGCAATATC
	R	CAAACCACAACCTAGAATGCAG
Endogenous allele at the Δ NT-M transgene integration site	F	GGAGACAGGATCTTCTGTAGC
	R	GTAGTCCTACCTGAGGGACCAG

Supplementary Table 3. Primer sequences used for Identification of transgene insertion sites.

Primer name	Primer sequence (5'-3')
G1HRD outer	GAGTACTCACATGAATCTGAGATGTC
G1HRD nested	GAGTATTCTGATCTGTCTACTGAGTGC
Δ NT3'UTR outer	GAGACAGGATCTTCTGTAGCTATGTAG
Δ NT3'UTR nested	TTTGACAAACCACAACCTAGAATGCAG

Supplementary Table 4. Primer sequences used for qPCR.

		Primer sequence (5'-3')
<i>Gata1</i>	F	CAGAACCGGCCTTCATCC
	R	TAGTGCATTGGGTGCCTGC
<i>Gapdh</i>	F	GTCGTGGAGTCTACTGGTGTCTT
	R	GAGATGATGACCCTTTTGGC

Supplementary methods

Mice

Experimental procedures involving animals are approved by the Institutional Animal Experiment Committee of the Tohoku University. Experiments were carried out in compliance with the Regulation for Animal Experiments in Tohoku University (2015MdA-001, 2018MdA-058, 2018MdA-245, 2019MdA-289). Mice were continuously monitored for survival and were humanely euthanized upon reaching predetermined endpoints. Mice having enlarged spleen over the midline of body at necropsy were defined as those developing leukemia. Hematopoietic indices of embryos were measured by collecting blood after decapitation with surgical scissors and using a Celltac- α autohemocytometer (Nihon Koden). The *Gata1.05* allele was identified through genomic polymerase chain reaction (PCR) using a pair of primers specific to the neomycin resistance gene [6]. *Gata1* transgenes were genotyped via PCR, using a primer set designed to target the region flanking exon 4 and exon 6 of *Gata1* cDNA (Supplementary Fig. 5A). Δ NTR-MH mice were produced by crossing *Gata1.05/X* mice carrying Δ NT-H or Δ NT-M transgene with Δ NT-M or Δ NT-H transgenic male mice, respectively. Specific primer sets were used to identify Δ NT-H and Δ NT-M transgenes (Supplementary Fig. 5B, C). Δ NTR-MM mice were generated by crossing *Gata1.05/X* mice carrying the Δ NT-M transgene with Δ NT-M transgenic male mice. To distinguish Δ NTR-MM from Δ NTR-M, we used a primer set designed to recognize the endogenous allele at the site where the Δ NT-M transgene was incorporated (Supplementary Fig. 5). The primer sequences used for mouse genotyping are shown in Supplementary Table 2.

Identification of insertion sites of transgenes

Transgene insertion sites were determined using the Universal Genomic Walker Kit from

Clontech Laboratories, following the manufacturer's instruction. In brief, we amplified fragments containing genome-transgene boundary sequences from the transgenic mouse genome through nested PCR. This was achieved using transgene-specific primers in conjunction with adaptor primers provided by the manufacturer. The sequences of transgene-specific primers are shown in Supplementary Table 3. DNA fragments were purified from agarose gel and cloned into a pGEM-T vector (Promega). Subsequently, sequencing of the cloned fragments was carried out using T7 and SP6 primers, employing BigDye Terminator v3.1 Cycle Sequencing Kit and ABI PRISM 3100 Genetic Analyzer (Applied Biosystems). After excluding fragment sequences originating from the fusion of two transgenes, sequence data were analyzed through the National Center for Biotechnology Information (<https://www.ncbi.nlm.nih.gov>) and the DNA Data Bank of Japan (<https://www.ddbj.nig.ac.jp/index-e.html>) websites. Schematic illustrations depicting the genomic regions surrounding the transgenes are shown in Supplementary Fig. 5.

Flow cytometry analysis

Mononuclear cells collected from fetal liver and spleen were suspended in phosphate-buffered saline (PBS) containing 2% fetal bovine serum (FBS). Fetal liver cells were labeled with fluorescein isothiocyanate (FITC)-conjugated anti-CD41 (eBioscience) and phycoerythrin (PE)-conjugated anti-CD61 (eBioscience) antibodies. Spleen cells were labeled with FITC-conjugated anti-CD41, PE-conjugated anti-CD71 (BioLegend) and allophycocyanin conjugated anti-cKit (BD Biosciences) antibodies. After two washes with PBS, the cells were resuspended in PBS containing 2% FBS and analyzed using FACS CaliburTM (Becton Dickinson Biosciences). Dead cells were excluded by propidium iodide.

RNA extraction and quantitative real-time PCR

CD41-positive cells were isolated using biotin anti-CD41 antibody (eBioscience) and

streptavidin-conjugated beads (Invitrogen). Total RNA from the CD41-positive cells was isolated using ISOGEN (NIPPON GENE). Subsequently, first-strand cDNA was synthesized using ReverTra Ace (TOYOBO). Quantitative real-time PCR was conducted utilizing the ABI PRISM 7300 sequence detector system and StepOnePlus Real-Time PCR System (Applied Biosystems) along with THUNDERBIRD SYBR qPCR Mix (TOYOBO). The data were normalized to the *Gapdh* mRNA level. The primer sequences employed for the expression analysis are provided in Supplementary Table 4.

Proplatelet formation assay

Mononuclear cells were suspended in CATCH-medium (doi: 10.1083/jcb.69.1.159) and overlaid on a discontinuous BSA gradient (2%/3%/4%/16% in CATCH-medium). After 1 hour, the upper half of the gradient was combined and washed with CATCH-medium. Subsequently, cells were resuspended in 2-ml IMDM-medium containing Nutridoma-SP (Behringer-Mannheim). After a 24 hour-incubation at 37°C, the frequencies of megakaryocytes forming proplatelets were assessed.

Histological and cytological analysis and microscope

Cytospin samples of bone marrow and spleen cells were prepared using a cytocentrifuge (Thermo Fisher Scientific). Peripheral blood smear samples and cytospin samples were stained with May–Grünwald staining solution (Merck) and Giemsa staining solution (Merck). Formalin-fixed tissue sections were stained with Hematoxylin-eosin and Watanabe's silver impregnation method. Images of mice were monitored by μ TOUGH-8000 (Olympus). Images of tissues were captured using a BX51 microscope (Olympus) and images of cells expressing GFP were captured using MZFLIII stereomicroscopes (Leica), and were photographed using a DP73 CCD-camera (Olympus).

Statistical analysis

All statistical analyses were done using JMP software (SAS Institute Inc.). Survival rates were analyzed using the Kaplan-Meier method. The data was analyzed using a Mann-Whitney U test. Mortality of various mouse groups were compared using the Log-rank test and Generalized Wilcoxon test.